Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cameron J Turtle

Showing results (61-70 of 129) with videos related to

Pageof 13
Sort By:
The Lancet. Respiratory Medicine|October 19, 2020
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromesDaniel E Leisman, Lukas Ronner, Rachel Pinotti, et al.
Nature Reviews. Clinical Oncology|February 26, 2021
Immunogenicity of CAR T cells in cancer therapyDimitrios L Wagner, Enrico Fritsche, Michael A Pulsipher, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 9, 2021
CMV and HSV Pneumonia After Immunosuppressive Agents for Treatment of Cytokine Release Syndrome Due to Chimeric Antigen Receptor-modified T (CAR-T)-Cell ImmunotherapyMadeleine R Heldman, Jimmy Ma, Jordan Gauthier, et al.
Molecular Therapy. Oncology|September 3, 2024
Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapySalvatore Fiorenza, Sheryl Y T Lim, George S Laszlo, et al.
Journal for Immunotherapy of Cancer|May 9, 2024
Stealth transgenes enable CAR-T cells to evade host immune responsesKorneel Grauwet, Trisha Berger, Michael C Kann, et al.
Transplantation and Cellular Therapy|May 21, 2025
Low Peripheral Blood Counts and Elevated Proinflammatory Cytokines Signal a Poor CD19 Chimeric Antigen Receptor T-cell Response in Acute Lymphoblastic LeukemiaKatelyn Burleigh, Kelly G Stratton, Jenny L Smith, et al.
Blood|October 25, 2019
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapyAlexandre V Hirayama, Jordan Gauthier, Kevin A Hay, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 13, 2019
Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell TherapyJulia Ruark, Erin Mullane, Nancy Cleary, et al.
Future Oncology (London, England)|June 22, 2021
Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignanciesNina Shah, Miguel-Angel Perales, Cameron J Turtle, et al.
Blood Advances|November 4, 2022
A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapyAlexandre V Hirayama, Cassie K Chou, Takahiro Miyazaki, et al.
Pageof 13

Showing results (61-70 of 129) with videos related to

Sort By:
Pageof 13
The Lancet. Respiratory Medicine|October 19, 2020
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromesDaniel E Leisman, Lukas Ronner, Rachel Pinotti, et al.
Nature Reviews. Clinical Oncology|February 26, 2021
Immunogenicity of CAR T cells in cancer therapyDimitrios L Wagner, Enrico Fritsche, Michael A Pulsipher, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 9, 2021
CMV and HSV Pneumonia After Immunosuppressive Agents for Treatment of Cytokine Release Syndrome Due to Chimeric Antigen Receptor-modified T (CAR-T)-Cell ImmunotherapyMadeleine R Heldman, Jimmy Ma, Jordan Gauthier, et al.
Molecular Therapy. Oncology|September 3, 2024
Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapySalvatore Fiorenza, Sheryl Y T Lim, George S Laszlo, et al.
Journal for Immunotherapy of Cancer|May 9, 2024
Stealth transgenes enable CAR-T cells to evade host immune responsesKorneel Grauwet, Trisha Berger, Michael C Kann, et al.
Transplantation and Cellular Therapy|May 21, 2025
Low Peripheral Blood Counts and Elevated Proinflammatory Cytokines Signal a Poor CD19 Chimeric Antigen Receptor T-cell Response in Acute Lymphoblastic LeukemiaKatelyn Burleigh, Kelly G Stratton, Jenny L Smith, et al.
Blood|October 25, 2019
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapyAlexandre V Hirayama, Jordan Gauthier, Kevin A Hay, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 13, 2019
Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell TherapyJulia Ruark, Erin Mullane, Nancy Cleary, et al.
Future Oncology (London, England)|June 22, 2021
Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignanciesNina Shah, Miguel-Angel Perales, Cameron J Turtle, et al.
Blood Advances|November 4, 2022
A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapyAlexandre V Hirayama, Cassie K Chou, Takahiro Miyazaki, et al.
Pageof 13